Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2018

May 15, 2018

SELL
$6.7 - $12.95 $670 - $1,295
-100 Closed
0 $0
Q4 2017

Mar 09, 2018

BUY
$5.07 - $7.92 $507 - $792
100
100 $1,000

Others Institutions Holding IMGN

About ImmunoGen, Inc.


  • Ticker IMGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 220,712,992
  • Description
  • ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and Pivekimab sun...
More about IMGN
Track This Portfolio

Track Marino, Stram & Associates LLC Portfolio

Follow Marino, Stram & Associates LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Marino, Stram & Associates LLC, based on Form 13F filings with the SEC.

News

Stay updated on Marino, Stram & Associates LLC with notifications on news.